QC
PHAT icon

Quadrature Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Quadrature Capital’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$134K Buy
+12,078
New +$153K ﹤0.01% 1184
2025
Q4 		– Sell
-30,272
Closed -$356K – 1568
2025
Q3 		$356K Buy
+30,272
New +$312K ﹤0.01% 624

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Quadrature Capital's PHAT Position: Q1 2026 in Review

Quadrature Capital opened a new position in Phathom Pharmaceuticals (PHAT) in Q1 2026: 12,078 shares worth $134K. The stake represents ﹤0.01% of the portfolio and ranks #1184 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in PHAT as recently as Q3 2025.

Quadrature Capital first reported a position in PHAT in Q3 2025 and has held it in 2 quarters since. The position peaked at $356K in Q3 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Quadrature Capital held 12,078 shares of Phathom Pharmaceuticals worth $134K as of Q1 2026.
  • Phathom Pharmaceuticals was a new Quadrature Capital position in Q1 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1184 holding.
  • Quadrature Capital first reported a position in Phathom Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Quadrature Capital's Phathom Pharmaceuticals position peaked at $356K in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.